Overcoming Endocrine Resistance in Breast Cancer
By A. Hanker, D. Sudhan, Carlos L. Arteaga. Cancer Cell, 2020
653 citations recorded by the source corpus.
Summary Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype. Treatment of ER+ breast cancer comprises interventions that suppress estrogen production and/or target the ER directly (overall labeled as endocrine therapy). While endocrine therapy has considerably reduced recurrence and mortality from breast cancer, de novo and acquired resistance to this treatment remains a major challenge. An increasing number of mechanisms of endocrine resistance have been reported, including somatic alterations, epigenetic changes, and changes in the tumor microenvironment. Here, we review recent advances in delineating mechanisms of resistance to endocrine therapies and potential strategies to overcome such resistance.
Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/79ec26c49422499f49e2e166db34c532034ef75f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Molecular Biology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones (2023, background): “This is clinically relevant, as there are ER BCa patients and AR prostate cancer patients who are not responsive to corresponding hormonal therapies.(53,54)”